PML: An emerging tumor suppressor and a target with therapeutic potential.
PML: An emerging tumor suppressor and a target with therapeutic potential.
复制标题
DOI：
--
复制
发表时间：
2009-09
期刊：
影响因子：
--
通讯作者：
Erin L. Reineke;H. Kao
中科院分区：
文献类型：
--
作者：
Erin L. Reineke;H. Kao
虽然早幼粒细胞白血病蛋白(PML)最初被发现为急性早幼粒细胞白血病(APL)的肿瘤抑制因子，但它在其他来源的癌症中的重要性尚未得到广泛研究。最近的研究表明，多种类型的癌症都表现出PML蛋白表达的降低，尽管导致这种下调的机制尚不清楚。PML的表达减少可导致细胞周期调控的丧失和细胞凋亡的阻止，这可能是促进肿瘤发生的关键事件。这些效应中的许多是由于PML核小体的大小和数量减少而导致细胞转录图谱的变化。几项小鼠研究证实了PML在肿瘤发生和癌症进展中的作用。重要的是，不仅要进一步确定PML作为肿瘤抑制因子的作用，而且要开始开发针对PML治疗的策略。
Though originally discovered as a tumor suppressor in Acute Promyelocytic Leukemia (APL), the importance of promyelocytic leukemia protein (PML) in cancers of other origins has not been widely studied. Recent studies have shown that multiple types of cancers show decreased expression of PML protein, though the mechanisms leading to this down-regulation are unknown. Decreased expression of PML can result in loss of cell cycle control and prevention of apoptosis and is likely a key event in the promotion of oncogenesis. Many of these effects are due to changes in the transcriptional profile of the cell as a result of decreased size and number of PML nuclear bodies. Several mouse studies confirm the contribution of PML to oncogenesis and cancer progression. It is important to not only further define a role for PML as a tumor suppressor, but also to begin to develop strategies to target PML therapeutically.